- Home
- XCUR vs OTLK Comparison
XCUR vs OTLK Comparison
Compare XCUR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XCUR
- OTLK
- Stock Information
- Founded
- XCUR 2011
- OTLK 2010
- Country
- XCUR United States
- OTLK United States
- Employees
- XCUR N/A
- OTLK N/A
- Industry
- XCUR Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XCUR Health Care
- OTLK Health Care
- Exchange
- XCUR Nasdaq
- OTLK Nasdaq
- Market Cap
- XCUR 59.0M
- OTLK 48.3M
- IPO Year
- XCUR N/A
- OTLK 2016
- Fundamental
- Price
- XCUR $7.86
- OTLK $1.71
- Analyst Decision
- XCUR
- OTLK Strong Buy
- Analyst Count
- XCUR 0
- OTLK 5
- Target Price
- XCUR N/A
- OTLK $9.60
- AVG Volume (30 Days)
- XCUR 5.7K
- OTLK 823.9K
- Earning Date
- XCUR 08-12-2025
- OTLK 08-13-2025
- Dividend Yield
- XCUR N/A
- OTLK N/A
- EPS Growth
- XCUR N/A
- OTLK N/A
- EPS
- XCUR N/A
- OTLK 0.83
- Revenue
- XCUR $500,000.00
- OTLK N/A
- Revenue This Year
- XCUR N/A
- OTLK N/A
- Revenue Next Year
- XCUR N/A
- OTLK $379.84
- P/E Ratio
- XCUR N/A
- OTLK $2.06
- Revenue Growth
- XCUR N/A
- OTLK N/A
- 52 Week Low
- XCUR $1.44
- OTLK $0.87
- 52 Week High
- XCUR $36.00
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- XCUR 31.28
- OTLK 46.49
- Support Level
- XCUR $7.53
- OTLK $1.65
- Resistance Level
- XCUR $8.96
- OTLK $1.97
- Average True Range (ATR)
- XCUR 0.69
- OTLK 0.12
- MACD
- XCUR -0.20
- OTLK -0.03
- Stochastic Oscillator
- XCUR 6.42
- OTLK 10.94
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.